As of October 1, 2026, new ICD-10-PCS codes are available for SeaStar Medical Holding Corporation’s Selective Cytopheretic Device (SCD) therapy. [3, 6] The codes allow hospitals to report, document, and bill for SCD therapy in patients with acute kidney injury (AKI) who require renal replacement therapy.
The codes provide a specific, standardized mechanism for hospitals to seek payment for QUELIMMUNE therapy, addressing a potential hurdle to wider adoption. [8]
The change is expected to reduce administrative burdens, improve reporting accuracy, and facilitate reimbursement. [3] It marks a step in commercializing SeaStar’s primary product and could support wider use in intensive care units for critically ill pediatric and adult patients.